Oklahoma Clinical Trials Report — April 2026

For Oklahomans considering participation in medical research, April 2026 presents a critical window of opportunity, especially for those interested in trials nearing their enrollment deadlines. Across the state, a total of 54 clinical trials are scheduled to conclude within the next 90 days. This urgency extends to healthy volunteers, with 3 of these rapidly closing studies still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, asthma, and deep venous thrombosis are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer
• Asthma
• Primary peritoneal cancer
• Stage III pancreatic cancer
• Stage IV pancreatic cancer
• Recurrent endometrial carcinoma
• Deep venous thrombosis
• Metastatic malignant solid neoplasm
• Anatomic stage III breast cancer
• Cancer weight loss

New Research Horizons: Hearing Health, Childhood Asthma, and Rheumatoid Arthritis

This April, Oklahoma welcomes 4 new clinical trials, offering fresh opportunities for residents to engage with cutting-edge medical research. While this number is lower than the 7 new trials that opened in March, the new studies are notable for their focus on significant health challenges and the involvement of prominent sponsors.

Among the standout new trials is a community-based study addressing hearing health among Native Americans. The University of California, San Francisco is sponsoring NCT07534098, "Intervention for Hearing Health Among Native Americans." This important study aims to enroll 400 participants to understand the cultural impact on hearing loss within Native American communities, particularly those who traditionally rely on oral communication. It proposes to implement a culturally relevant "Talking Circles" intervention, offering a unique approach to health research.

Another significant new opportunity comes from AstraZeneca, a major industry sponsor. They are launching NCT07525375, a Phase 2 study investigating lung function in children aged 4 to less than 12 years with asthma. This trial will evaluate two different doses of inhaled glycopyrronium when taken with BFF compared to BFF alone, with the goal of improving lung function for its 69 participants. This study represents a crucial step in developing better treatment options for younger asthma patients.

For adults living with rheumatoid arthritis, the University of Oklahoma is sponsoring NCT07534332, a Phase 2 study titled "Disulfiram in Rheumatoid Arthritis." This trial, designed for 20 participants, explores the potential of disulfiram as a treatment. The research acknowledges the common co-occurrence of obesity with rheumatoid arthritis, which can worsen disease activity and treatment response, suggesting a broader impact on inflammation and metabolic health.

In addition to these, a new trial focusing on elbow fractures has also opened, further diversifying the research landscape this month. These new studies cover a range of conditions, including:

• Asthma
• Elbow fractures
• Inflammation
• Noise-induced hearing loss
• Obesity
• Rheumatoid arthritis

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 4 new trials launched this month, 2 are actively seeking healthy volunteers. Statewide, a total of 61 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing health knowledge.

Clinical trials in Oklahoma are designed to be inclusive, with eligibility extending across various demographics. This month's new trials include opportunities for both children and older adults. Specifically, 2 of the new trials are open to children, and 2 also include older adults, ensuring that a broad spectrum of the population can participate in these important studies.

Oklahoma's Research Footprint: Where to Find Trials

Oklahoma's clinical research efforts are spread across the state, with 804 trials currently recruiting in 23 cities and at 415 research sites. This broad distribution means that many residents have access to trial opportunities within a reasonable distance.

This month's new trials are concentrated in two key locations: 3 new studies opened in Oklahoma City, and 1 new trial launched in Tahlequah. This geographic spread, while focused on these two cities for new openings, contributes to the overall accessibility of research across the state. Oklahoma City continues to be a central hub for medical research, while the opening in Tahlequah highlights efforts to engage diverse communities in health studies.

The types of interventions being studied are varied, with drug trials and behavioral interventions leading the way among the new studies. Academic institutions, including the University of Oklahoma and the University of California, San Francisco, are playing a significant role in sponsoring new research, alongside industry leaders like AstraZeneca.

As we move through spring, the focus will remain on the continued enrollment in these new and ongoing trials, particularly those with upcoming deadlines. Oklahomans interested in contributing to medical progress are encouraged to explore these opportunities, knowing their participation can make a tangible difference in the future of healthcare.